CurrentBlue Cross Blue Shield - MassachusettsPolicy 794

Peripheral nerve radiofrequency ablation and cryoneurolysis for pain

Defines Blue Cross Blue Shield Massachusetts commercial and Medicare policy positions on radiofrequency ablation (RFA) and cryoneurolysis of peripheral nerves for various pain indications (knee osteoarthritis, total knee arthroplasty, plantar fasciitis, occipital neuralgia/cervicogenic headache, and other peripheral pain). Also specifies prior authorization requirements and lists related CPT codes for informational purposes.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyPeripheral nerve radiofrequency ablation and cryoneurolysis for pain

Policy CodePolicy 794

Change TypeAnnual review; coding clarification; investigational addition (2021)

Effective Date

Next Review Date

Key ActionPrecertification/preauthorization is required for all products if the procedure is performed inpatient; for outpatient services check product-specific prior authorization requirements and member contract benefits.

POLICY UPDATE CHANGES

2/2021: Cryoneurolysis was added to the investigational statement on occipital neuralgia or cervicogenic headache; effective 2/1/2021.

11/2024: Annual policy review with description, summary, and references updated; policy statements unchanged.

6/2024: Clarified coding information.

4Investigational indications named

2CPT codes listed

794Policy number

Coverage Summary

Scope: Defines Blue Cross Blue Shield Massachusetts commercial and Medicare positions on radiofrequency ablation (RFA) and cryoneurolysis of peripheral nerves for pain, covering indications including knee osteoarthritis (including genicular nerve RFA), total knee arthroplasty (cryoneurolysis), plantar fasciitis, occipital neuralgia/cervicogenic headache, and other peripheral pain conditions; also specifies prior authorization requirements and lists related CPT codes for informational purposes.

Coverage stance overview: mixed — the policy considers the listed peripheral nerve RFA and cryoneurolysis procedures investigational (not covered) for the named indications, with the exception of facet joint pain which is not included in the investigational listing.

Policy number794

SubjectPeripheral nerve radiofrequency ablation and cryoneurolysis for pain

Last review2024-11

StatusCURRENT

Investigational / Not Medically Necessary Indications

The following peripheral nerve ablation/cryoneurolysis procedures are considered investigational (not covered) for commercial members except where noted:

ANY of the following

Radiofrequency ablation (RFA) of peripheral nerves to treat pain associated with knee osteoarthritis or plantar fasciitis is considered investigational.
Cryoneurolysis of peripheral nerves to treat pain associated with knee osteoarthritis or total knee arthroplasty is considered investigational.
Radiofrequency ablation or cryoneurolysis of peripheral nerves to treat pain associated with occipital neuralgia or cervicogenic headache is considered investigational.
Ablation of peripheral nerves to treat pain is considered investigational in all other conditions, with the exception of facet joint pain.

Coding

Investigational CPT codes (informational list)CPTNot Covered

64640	Destruction by neurolytic agent; other peripheral nerve or branch
64624	Destruction by neurolytic agent; genicular nerve branches including imaging guidance, when performed

Informational note: Inclusion or exclusion of a CPT code in this policy is for informational purposes only and does not constitute or imply member coverage or provider reimbursement. Providers must refer to member contract benefits and report services using current standard procedure and modifier codes when billing.

Provider Actions

Prior Authorization

Precertification required for inpatient services

Precertification/preauthorization is required for all products if the procedure is performed inpatient.

Prior Authorization

Outpatient prior authorization varies by product

For outpatient services, prior authorization may be required depending on the product and the statement in the policy (several product lines indicate 'This is not a covered service' for outpatient). Providers must check product-specific requirements and member contract benefits.

Background and Evidence Summary

Background: Radiofrequency ablation (RFA) is a minimally invasive technique that uses heat and coagulation necrosis applied via a needle electrode to ablate nerve tissue; variants include standard, pulsed, and cooled RFA. Cryoneurolysis applies extreme cold to induce Wallerian degeneration with temporary disruption of nerve conduction and potential regeneration over months.

Evidence summary and conclusion: Evidence for peripheral (non‑spine) applications — specifically genicular nerve RFA for knee osteoarthritis, cryoneurolysis for knee OA or prior to total knee arthroplasty, RFA for plantar fasciitis, and RFA/cryoneurolysis for occipital or cervicogenic headache — is heterogeneous. Randomized trials and systematic reviews show some short‑term (around 3–6 months) benefits in some studies but with substantial heterogeneity and inconsistent durability; overall the evidence is insufficient to determine a net health benefit for the listed peripheral indications.

Evidence item	Summary
Knee OA RCTs and systematic reviews
RCTs and meta-analyses show some short-term benefit (3-6 months) with heterogeneity; overall insufficient evidence for durable net health benefit
Cryoneurolysis knee OA/TKA trials
Two RCTs (total N=304) with mixed results; short-term benefits not consistently durable
Plantar fasciitis RFA
Two small RCTs and a meta-analysis with low-quality evidence and no consistent pain improvement
Occipital/cervicogenic headache
No RCTs for RFA in chronic occipital neuralgia; limited and inconclusive trials for cervicogenic headache

Definitions

Radiofrequency ablation (RFA): Minimally invasive method using heat and coagulation necrosis via a needle electrode to ablate nerve tissue; includes standard, pulsed, and cooled RFA variants.

Cryoneurolysis: Application of extreme cold to cause Wallerian degeneration of a nerve resulting in temporary disruption of conduction with potential regeneration over months.

Revision History

2/2021added

Cryoneurolysis was added to the investigational statement for occipital neuralgia or cervicogenic headache; effective 2/1/2021. (Policy statements otherwise unchanged.)

6/2024clarified

Clarified coding information. (Policy statements unchanged.)

11/2024revisedLatest

Annual policy review: description, summary, and references updated; policy statements unchanged.